(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 March 2006 (23.03.2006)

PCT

(10) International Publication Number
WO 2006/029879 A2

(51) International Patent Classification:
C07K 16/46 (2006.01)

(21) International Application Number:
PCT/EP2005/009968

(22) International Filing Date:
16 September 2005 (16.09.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

04022158.2	17 September 2004 (17.09.2004)	EP
04030546.8	23 December 2004 (23.12.2004)	EP

(71) Applicant *(for all designated States except US)*: **F.HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ENDL, Josef** [DE/DE]; Ulmenstrasse 12, 82362 Weilheim (DE). **EUGUI, Elsie** [US/US]; 2513 Hastings Dr., Belmont, CA 94002 (US). **FUENTES, Maria** [US/US]; 1413 South Mary Ave., Sunnyvale, Ca 94087 (US). **GRAUS, Yvo** [NL/NL]; Werdorperwaard 3, NL-3984 PR Odijk (NL). **LABRIJN, Aran** [NL/NL]; 2e Jan van der Heijdenstraat 66-3R, NL-1074 XW Amsterdam (NL). **LANZENDOERFER, Martin** [DE/DE]; Hofmairstrasse 25a, 82327 Tutzing (DE). **PARREN, Paul** [NL/NL]; Werdorperwaard 17, NL-3984 PR Odijk (NL). **REBERS, Frank** [NL/NL]; Adriaan Menninckkwartier 34, NL-3554 CT Utrecht (NL). **SCHUMACHER, Ralf** [DE/DE]; Hochfeldstrasse 78, 82377 Penzberg (DE). **SEEBER, Stefan** [DE/DE]; Saalanger 34, 82377 Penzberg (DE). **VAN DE WINKEL, Jan** [NL/NL]; Verlengde Slotlaan 80, NL-3707 CK Zeist (NL). **VAN VUGT, Martine** [NL/NL]; Fluweelmos 6, NL-3994 KR Houten (NL).

(74) Agent: **SCHREINER, Siegfried**; Roche Diagnostics GmbH, Patent Department (TR-E), Postfach 11 52, 82372 Penzberg (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv)) for US only*

Published:
— *without international search report and to be republished upon receipt of that report*
— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** ANTI-OX40L ANTIBODIES

(57) **Abstract:** This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

WO 2006/029879 A2